ATOS:NSD-Atossa Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.35

Change

-0.04 (-2.88)%

Market Cap

USD 0.18B

Volume

2.37M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Atossa Therapeutics Inc (ATOS) Stock Analysis:
Based on the Atossa Therapeutics Inc stock forecasts from 0 analysts, the average analyst target price for Atossa Therapeutics Inc is not available over the next 12 months. Atossa Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Atossa Therapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Atossa Therapeutics Inc’s stock price was USD 1.35. Atossa Therapeutics Inc’s stock price has changed by -0.14% over the past week, -0.62% over the past month and -12.34% over the last year.

About

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing ATOS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.63% 47% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.63% 47% F 23% F
Trailing 12 Months  
Capital Gain -12.34% 83% B 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.34% 83% B 43% F
Trailing 5 Years  
Capital Gain -91.85% 16% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.85% 16% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -1.23% 36% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.23% 35% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 59.09% 51% F 28% F
Risk Adjusted Return -2.08% 36% F 23% F
Market Capitalization 0.18B 45% F 33% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.80 72% C- 60% D-
Price / Cash Flow Ratio -15.98 76% C 80% B-
EV/EBITDA 0.09 82% B- 96% A
Management Effectiveness  
Return on Equity -30.76% 78% C+ 35% F
Return on Invested Capital -88.42% 23% F 9% F
Return on Assets -16.12% 73% C 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.21 32% F 20% F
Short Percent 13.66% 10% F 12% F
Beta 1.97 16% F 12% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.